Payment overview · 2025
General Payments
$184.77
13 reported records · 3 companies
Healthcare provider profile · identity verified
Felicia Cooper
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PADUCAH, KY · NPI 1508314212
Verified facts
What the public records show
CMS Open Payments records show Felicia Cooper received $184.77 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 82.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 279 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $152.07 | 82.3% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.12 | 9.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.58 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $184.77 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $152.07 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $94.86 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 279 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
279 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 384 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 381 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 338 | 80 |
| Lisinopril | Lisinopril | 289 | 80 |
| Ozempic | Semaglutide | 279 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 64 |
| Gabapentin | Gabapentin | 253 | 49 |
| Metformin Hcl | Metformin Hcl | 242 | 62 |
| Losartan Potassium | Losartan Potassium | 241 | 61 |
| Omeprazole | Omeprazole | 217 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 209 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 48 |
| Simvastatin | Simvastatin | 199 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 47 |
| Trazodone Hcl | Trazodone Hcl | 172 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 143 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 29 |
| Montelukast Sodium | Montelukast Sodium | 111 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 22 |
| Furosemide | Furosemide | 102 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 23 |
| Meloxicam | Meloxicam | 92 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 20 |
| Eliquis | Apixaban | 80 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 23 |
| Methylprednisolone | Methylprednisolone | 67 | 57 |
| Alprazolam | Alprazolam | 66 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 27 |
| Bupropion Xl | Bupropion Hcl | 63 | 18 |
| Potassium Chloride | Potassium Chloride | 63 | 18 |
| Jardiance | Empagliflozin | 60 | 13 |
| Ondansetron Odt | Ondansetron | 60 | 27 |
| Buspirone Hcl | Buspirone Hcl | 57 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 14 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Nifedipine Er | Nifedipine | 47 | 11 |
| Carvedilol | Carvedilol | 45 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Nystatin | Nystatin | 45 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 42 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | 11 |
| Spironolactone | Spironolactone | 40 | 11 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 11 |
| Famotidine | Famotidine | 38 | 13 |
| Alendronate Sodium | Alendronate Sodium | 37 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | suppressed |
| Prednisone | Prednisone | 34 | 21 |
| Clonidine Hcl | Clonidine Hcl | 33 | 14 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 20 |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | 11 |
| Estradiol | Estradiol | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 25 |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 13 |
| Glipizide | Glipizide | 25 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Estarylla | Norgestimate-Ethinyl Estradiol | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Nystop | Nystatin | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $184.77 · 13 records | ABBVIE INC. | Cologuard Collection Kit, Ozempic, QULIPTA, Rybelsus, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error